trilaciclib
trilaciclib: developed by 1 company · 3 clinical trials tracked.
trilaciclib evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could trilaciclib → GTHX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| G1 Therapeutics, Inc. (GTHX) | Phase 3 |
Clinical Trials (3)
ToPCourT: A Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC)
Primary endpoint: Objective Response
Study of Trilaciclib and Lurbinectedin in Small Cell Lung Cancer
Primary endpoint: The proportion of grade 4 neutropenia
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Primary endpoint: Duration of Severe (Grade 4) Neutropenia in Cycle 1
Frequently asked questions
Who is developing trilaciclib?
trilaciclib is being developed by G1 Therapeutics, Inc..
How many clinical trials involve trilaciclib?
BioSniper tracks 3 clinical trials involving trilaciclib.